EVX B1
Alternative Names: EVX-B1Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Evaxion Biotech
- Class Bacterial vaccines; Protein vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in Denmark
- 28 Oct 2024 No recent reports of development identified for preclinical development in Skin-and-soft-tissue-infections in Denmark
- 31 Jul 2023 Immunogenicity data from a preclinical studies in Methicillin-resistant Staphylococcus aureus infections released by Evaxion Biotech